FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169350985> ?p ?o ?g. }

• W3169350985 endingPage "9533" @default.
• W3169350985 startingPage "9533" @default.
• W3169350985 abstract "9533 Background: First line IPI+PD1 induces long-term response in 36% of MM patients (pts); however, the majority of pts will progress and may require further treatment, which is yet to be established. We studied the patterns of progressive disease (PD) on 1st line IPI+PD1, and the management and outcomes in MM pts. Methods: Demographics, disease characteristics, nature of PD, subsequent treatments and outcomes were examined in MM pts with PD on 1st line IPI+PD1. Multivariable analyses (MVA) identified factors associated with patterns of PD: innate resistance (IR) = PD as best response or stable disease (SD) < 6 mo; acquired resistance (AR) = PD after initial response or SD ≥ 6 mo. Results: 310 MM pts from 14 melanoma centres were included; 208 (67%) had PD during and 102 (33%) after ceasing IPI+PD1. Overall med. progression-free survival (mPFS) was 2.8 mo (CI 95% 2.7 – 3.0); 187 pts (60%) had IR (mPFS 2.2 [2.1 – 2.5]), 112 pts (36%) had AR (mPFS 8.5 [7.2 – 10.2]) and 11 pts (4%) had pseudoprogression, i.e. PD followed by response without changing treatment (mPFS 2.7 mo [1.4 – NA]). On MVA, pts with ECOG PS ≥ 1 were more likely to have IR vs AR; and within IR pts, those with head & neck primary melanomas and lung metastases were more likely to have PD < 1.5 mo. Most pts with IR (68%) had PD in multiple sites, while 61% AR pts had PD in a single site. Brain was most common site of single organ PD; 49% of IR and 41% of AR. Med. follow-up from PD was 32.7 mo (28.1 – 36.8). After PD, 61 pts (20%) had best supportive care (26% of IR and 11% of AR pts). 259 pts (80%) received further treatment: 39% IR pts had systemic treatment (ST) only and 27% had ST + local; 31% AR pts had ST only and 39% had ST + local. Of 200 pts (65%) who had ST(+/-local), 54% had 1 line of ST and 46% had ≥ 2; 1st line ST (ST1) was BRAF/MEKi in 36% of pts, PD1 in 32%, IPI+PD1 in 7%, investigational drugs in 11%, chemotherapy in 9% and others in 5%. ORR in IR pts was lower than in AR pts for every type of ST1 (see Table). Med. OS from PD was 11.4 mo (CI 95% 9.6 – 16.1); IR 6.4 mo (CI 95% 5.6 – 10.2) and AR 26.1 mo (CI 95% 17.1 – NA). Conclusions: These data suggest longer OS from PD for AR vs IR pts independent of ST type. BRAF/MEKi, rechallenge with PD1+/-IPI and investigational drugs showed activity after PD on IPI+PD1, while chemotherapy has no role in this context.[Table: see text]" @default.
• W3169350985 created "2021-06-22" @default.
• W3169350985 creator A5007787317 @default.
• W3169350985 creator A5009968141 @default.
• W3169350985 creator A5022520811 @default.
• W3169350985 creator A5025067315 @default.
• W3169350985 creator A5025478490 @default.
• W3169350985 creator A5036987287 @default.
• W3169350985 creator A5050031536 @default.
• W3169350985 creator A5052403208 @default.
• W3169350985 creator A5056132643 @default.
• W3169350985 creator A5059961435 @default.
• W3169350985 creator A5062851041 @default.
• W3169350985 creator A5064026461 @default.
• W3169350985 creator A5064923908 @default.
• W3169350985 creator A5065006250 @default.
• W3169350985 creator A5065819179 @default.
• W3169350985 creator A5070576000 @default.
• W3169350985 creator A5082278497 @default.
• W3169350985 creator A5083026922 @default.
• W3169350985 creator A5083061830 @default.
• W3169350985 creator A5088390068 @default.
• W3169350985 date "2021-05-20" @default.
• W3169350985 modified "2023-10-17" @default.
• W3169350985 title "Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients." @default.
• W3169350985 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.9533" @default.
• W3169350985 hasPublicationYear "2021" @default.
• W3169350985 type Work @default.
• W3169350985 sameAs 3169350985 @default.
• W3169350985 citedByCount "1" @default.
• W3169350985 countsByYear W31693509852023 @default.
• W3169350985 crossrefType "journal-article" @default.
• W3169350985 hasAuthorship W3169350985A5007787317 @default.
• W3169350985 hasAuthorship W3169350985A5009968141 @default.
• W3169350985 hasAuthorship W3169350985A5022520811 @default.
• W3169350985 hasAuthorship W3169350985A5025067315 @default.
• W3169350985 hasAuthorship W3169350985A5025478490 @default.
• W3169350985 hasAuthorship W3169350985A5036987287 @default.
• W3169350985 hasAuthorship W3169350985A5050031536 @default.
• W3169350985 hasAuthorship W3169350985A5052403208 @default.
• W3169350985 hasAuthorship W3169350985A5056132643 @default.
• W3169350985 hasAuthorship W3169350985A5059961435 @default.
• W3169350985 hasAuthorship W3169350985A5062851041 @default.
• W3169350985 hasAuthorship W3169350985A5064026461 @default.
• W3169350985 hasAuthorship W3169350985A5064923908 @default.
• W3169350985 hasAuthorship W3169350985A5065006250 @default.
• W3169350985 hasAuthorship W3169350985A5065819179 @default.
• W3169350985 hasAuthorship W3169350985A5070576000 @default.
• W3169350985 hasAuthorship W3169350985A5082278497 @default.
• W3169350985 hasAuthorship W3169350985A5083026922 @default.
• W3169350985 hasAuthorship W3169350985A5083061830 @default.
• W3169350985 hasAuthorship W3169350985A5088390068 @default.
• W3169350985 hasConcept C121608353 @default.
• W3169350985 hasConcept C126322002 @default.
• W3169350985 hasConcept C143998085 @default.
• W3169350985 hasConcept C2777658100 @default.
• W3169350985 hasConcept C2777701055 @default.
• W3169350985 hasConcept C2781053074 @default.
• W3169350985 hasConcept C2781433595 @default.
• W3169350985 hasConcept C2993493390 @default.
• W3169350985 hasConcept C2994587330 @default.
• W3169350985 hasConcept C3019258254 @default.
• W3169350985 hasConcept C502942594 @default.
• W3169350985 hasConcept C71924100 @default.
• W3169350985 hasConcept C90924648 @default.
• W3169350985 hasConceptScore W3169350985C121608353 @default.
• W3169350985 hasConceptScore W3169350985C126322002 @default.
• W3169350985 hasConceptScore W3169350985C143998085 @default.
• W3169350985 hasConceptScore W3169350985C2777658100 @default.
• W3169350985 hasConceptScore W3169350985C2777701055 @default.
• W3169350985 hasConceptScore W3169350985C2781053074 @default.
• W3169350985 hasConceptScore W3169350985C2781433595 @default.
• W3169350985 hasConceptScore W3169350985C2993493390 @default.
• W3169350985 hasConceptScore W3169350985C2994587330 @default.
• W3169350985 hasConceptScore W3169350985C3019258254 @default.
• W3169350985 hasConceptScore W3169350985C502942594 @default.
• W3169350985 hasConceptScore W3169350985C71924100 @default.
• W3169350985 hasConceptScore W3169350985C90924648 @default.
• W3169350985 hasIssue "15_suppl" @default.
• W3169350985 hasLocation W31693509851 @default.
• W3169350985 hasOpenAccess W3169350985 @default.
• W3169350985 hasPrimaryLocation W31693509851 @default.
• W3169350985 hasRelatedWork W2123363005 @default.
• W3169350985 hasRelatedWork W2171124087 @default.
• W3169350985 hasRelatedWork W2332691537 @default.
• W3169350985 hasRelatedWork W2513285370 @default.
• W3169350985 hasRelatedWork W2550950468 @default.
• W3169350985 hasRelatedWork W2773756552 @default.
• W3169350985 hasRelatedWork W2888298425 @default.
• W3169350985 hasRelatedWork W2963333658 @default.
• W3169350985 hasRelatedWork W3154605418 @default.
• W3169350985 hasRelatedWork W4292594376 @default.
• W3169350985 hasVolume "39" @default.
• W3169350985 isParatext "false" @default.
• W3169350985 isRetracted "false" @default.
• W3169350985 magId "3169350985" @default.
• W3169350985 workType "article" @default.